Article Details

Catalent to invest $350m in US drug substance facility - BioPharma Reporter

Retrieved on: 2022-04-22 15:45:10

Tags for this article:

Click the tags to see associated articles and topics

Catalent to invest $350m in US drug substance facility - BioPharma Reporter. View article details on hiswai:

Excerpt

Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product ...

Article found on: www.biopharma-reporter.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up